BR112015021443A2 - novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os - Google Patents

novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os

Info

Publication number
BR112015021443A2
BR112015021443A2 BR112015021443A BR112015021443A BR112015021443A2 BR 112015021443 A2 BR112015021443 A2 BR 112015021443A2 BR 112015021443 A BR112015021443 A BR 112015021443A BR 112015021443 A BR112015021443 A BR 112015021443A BR 112015021443 A2 BR112015021443 A2 BR 112015021443A2
Authority
BR
Brazil
Prior art keywords
abexinostate
crystalline form
salt
preparation
pharmaceutical compositions
Prior art date
Application number
BR112015021443A
Other languages
English (en)
Inventor
Pimont-Garro Anne
Letellier Philippe
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015021443(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of BR112015021443A2 publication Critical patent/BR112015021443A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo patente de invenção "novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os" a presente invenção refere-se ao tosilato de abexinostato de fórmula (ii): e a sua forma cristalina i, caracterizada pelo seu diagrama de difração de raios x por pó, seu espectro de raman e seu espectro 13c cp/mas nmr de estado sólido.
BR112015021443A 2013-03-04 2014-03-03 novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os BR112015021443A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2014/050455 WO2014135776A1 (fr) 2013-03-04 2014-03-03 Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BR112015021443A2 true BR112015021443A2 (pt) 2017-07-18

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021443A BR112015021443A2 (pt) 2013-03-04 2014-03-03 novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os

Country Status (39)

Country Link
US (3) US9115108B2 (pt)
EP (2) EP3252044A1 (pt)
JP (2) JP6449177B2 (pt)
CN (2) CN105263917B (pt)
AR (1) AR094935A1 (pt)
AU (2) AU2014224456B2 (pt)
BR (1) BR112015021443A2 (pt)
CA (1) CA2903369C (pt)
CL (1) CL2015002488A1 (pt)
CR (1) CR20150456A (pt)
CY (1) CY1119147T1 (pt)
DK (1) DK2964622T3 (pt)
DO (1) DOP2015000215A (pt)
EA (2) EA030689B1 (pt)
ES (1) ES2632471T3 (pt)
FR (1) FR3002733B1 (pt)
GE (1) GEP201706760B (pt)
HK (1) HK1220965A1 (pt)
HR (1) HRP20171041T1 (pt)
HU (1) HUE035299T2 (pt)
IL (1) IL241038B (pt)
JO (1) JO3402B1 (pt)
LT (1) LT2964622T (pt)
MA (1) MA38423B1 (pt)
ME (1) ME02814B (pt)
MX (1) MX355436B (pt)
MY (1) MY192027A (pt)
NI (1) NI201500122A (pt)
PE (1) PE20151591A1 (pt)
PL (1) PL2964622T3 (pt)
PT (1) PT2964622T (pt)
RS (1) RS56224B1 (pt)
SG (1) SG11201506952YA (pt)
SI (1) SI2964622T1 (pt)
TN (1) TN2015000367A1 (pt)
TW (1) TWI506023B (pt)
UA (1) UA118550C2 (pt)
UY (1) UY35356A (pt)
WO (1) WO2014135776A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AP2015008381A0 (en) 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
AU2015311905B2 (en) * 2014-09-03 2020-03-05 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl)-N-{2-(4-(hydroxycarbamoyl) phenoxy)ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
AU2004230889B2 (en) * 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2964622T (pt) 2017-07-13
CL2015002488A1 (es) 2016-03-11
US20170313671A1 (en) 2017-11-02
GEP201706760B (en) 2017-10-25
HUE035299T2 (en) 2018-05-02
EA201891023A1 (ru) 2019-03-29
AU2014224456A8 (en) 2015-10-22
MY192027A (en) 2022-07-23
CN105263917B (zh) 2018-11-20
EP3252044A1 (fr) 2017-12-06
TN2015000367A1 (fr) 2017-01-03
US9115108B2 (en) 2015-08-25
EA030689B1 (ru) 2018-09-28
WO2014135776A1 (fr) 2014-09-12
MA38423A1 (fr) 2017-02-28
AU2014224456A1 (en) 2015-10-08
JP6449177B2 (ja) 2019-01-09
DOP2015000215A (es) 2015-09-30
JP2016510735A (ja) 2016-04-11
US10150748B2 (en) 2018-12-11
UY35356A (es) 2014-09-30
PL2964622T3 (pl) 2017-10-31
NI201500122A (es) 2018-10-18
FR3002733B1 (fr) 2015-08-14
US20150315167A1 (en) 2015-11-05
MX2015011566A (es) 2016-06-24
CN109734690B (zh) 2023-08-11
HK1220965A1 (zh) 2017-05-19
JO3402B1 (ar) 2019-10-20
AU2018202881A1 (en) 2018-05-17
RS56224B1 (sr) 2017-11-30
CR20150456A (es) 2015-10-21
EP2964622B1 (fr) 2017-04-19
AU2014224456B2 (en) 2018-01-25
MA38423B1 (fr) 2017-10-31
DK2964622T3 (en) 2017-07-31
CN105263917A (zh) 2016-01-20
EA039113B1 (ru) 2021-12-06
CY1119147T1 (el) 2018-02-14
TW201434822A (zh) 2014-09-16
ES2632471T3 (es) 2017-09-13
AU2018202881B2 (en) 2020-02-27
TWI506023B (zh) 2015-11-01
CN109734690A (zh) 2019-05-10
MX355436B (es) 2018-04-18
AR094935A1 (es) 2015-09-09
JP6720280B2 (ja) 2020-07-08
LT2964622T (lt) 2017-08-10
SG11201506952YA (en) 2015-10-29
IL241038A0 (en) 2015-11-30
EP2964622A1 (fr) 2016-01-13
FR3002733A1 (fr) 2014-09-05
US20140249215A1 (en) 2014-09-04
IL241038B (en) 2019-09-26
HRP20171041T1 (hr) 2017-10-06
CA2903369A1 (en) 2014-09-12
PE20151591A1 (es) 2015-11-06
NZ712380A (en) 2020-10-30
EA201591530A1 (ru) 2016-01-29
ME02814B (me) 2018-01-20
SI2964622T1 (sl) 2017-10-30
CA2903369C (en) 2021-06-08
UA118550C2 (uk) 2019-02-11
JP2019069955A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
BR112015021443A2 (pt) novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BRPI0600795B8 (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
UA118549C2 (uk) 2,3-дизаміщені похідні 1-ацил-4-аміно-1,2,3,4-тетрагідрохіноліну та їх застосування як інгібіторів бромодомену
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
BRPI0600796B8 (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2016001095A (es) Sales de dasatinib en forma cristalina.
WO2015042414A8 (en) Multicyclic compounds and methods of using same
CR20120655A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν
BR112015006243A2 (pt) agentes antibacterianos de fenicol
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
BR112016002724A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica
BR112014009217A2 (pt) antibacterianos à base de fenicol
BR112015029454A2 (pt) corantes de ácido, processo para a produção dos mesmos e seu uso
AR094866A1 (es) Formas cristalinas de un inhibidor de la prolil hidroxilasa
TH151188A (th) รูปผลึกเดลตาของเกลืออาร์จินีน (arginine) ของเพอรินโดพริล (perindopril), กระบวนการสำหรับการเตรียมสารดังกล่าว และองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2660 DE 28-12-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.